A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand

Clinical Rheumatology

Volumn 34, Issue 11, 2015, Pages 1921-1927

  Chang, Winston S J ^a   Schollum, Joanna ^a   White, Douglas H N ^a,b   Solanki, Kamal K ^a,b  

^a WAIKATO HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Autoantibodies; Diffuse cutaneous systemic sclerosis; Limited cutaneous systemic sclerosis; Scleroderma; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; CENTROMERE PROTEIN A ANTIBODY; CENTROMERE PROTEIN B ANTIBODY; FIB ANTIBODY; KU ANTIBODY; NOR90 ANTIBODY; PLATELET DERIVED GROWTH FACTOR RECEPTOR ANTIBODY; PM100 ANTIBODY; PM75 ANTIBODY; RNA POLYMERASE III ANTIBODY; RO 52 ANTIBODY; RO ANTIBODY; RP11 ANTIBODY; RP155 ANTIBODY; SCL 70 ANTIBODY; TH ANTIBODY; TO ANTIBODY; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; AUTOANTIGEN; CENTROMERE PROTEIN A; DNA DIRECTED RNA POLYMERASE III; NONHISTONE PROTEIN; SS-A ANTIBODIES;

ADULT; AGED; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DATA BASE; FEMALE; HUMAN; IMMUNOLOGY TEST KIT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEW ZEALAND; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; BLOOD; CLASSIFICATION; IMMUNOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOANTIGENS; CHROMOSOMAL PROTEINS, NON-HISTONE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; RNA POLYMERASE III; SCLERODERMA, SYSTEMIC;

EID: 84945454715     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-015-2981-3     Document Type: Article

References (28)

1. LeRoy EC et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202–205
2. Nihtyanova SI, Denton CP (2010) Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 6(2):112–116
3. Ho KT, Reveille J (2003) The clinical relevance of autoantibodies in scleroderma. Arthritis Research and Therapy 5(2):80–93
4. Krzyszczak ME et al (2011) Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. Clin Rheumatol 30(10):1333–1339
5. van den Hoogen F et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 72(11):1747–1755
6. Reveille JD et al (2001) Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 30(5):332–346
7. Meier FM et al (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 71(8):1355–1360
8. Mehra S et al (2013) Autoantibodies in systemic sclerosis. Autoimmun Rev 12(3):340–354
9. Hudson M et al (2012) Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 14(2):R50
10. Okano Y, Steen VD, Medsger TA Jr (1993) Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 119(10):1005–1013
11. Okano Y, Medsger TA Jr (1990) Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 33(12):1822–1828
12. Oddis CV et al (1992) Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum 35(10):1211–1217
13. Mahler M et al (2011) Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA. Clin Chim Acta 412(21–22):1937–1943
14. Harvey GR et al (1999) Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol 117(2):395–402
15. Meyer OC et al (2007) Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 34(1):104–109
16. Shoenfeld Y et al (1996) Anti-topoisomerase-I and clinical findings in systemic sclerosis (scleroderma). Isr J Med Sci 32(7):537–542
17. Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35(1):35–42
18. Bardoni A et al (2003) Autoantibodies to RNA-polymerases in Italian patients with systemic sclerosis. Clin Exp Rheumatol 21(3):301–306
19. Meyer O et al (2010) Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J Rheumatol 37(1):125–130
20. Hesselstrand R et al (2003) The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 42(4):534–540
21. Parker JC, Burlingame RW, Bunn CC (2009) Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis. J Autoimmune Dis 6:2
22. Dick T et al (2002) Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis. Ann Rheum Dis 61(2):121–127
23. Kikuchi M, Inagaki T (2000) Bibliographical study of the concurrent existence of anticentromere and antitopoisomerase I antibodies. Clin Rheumatol 19(6):435–441
24. Jablonska S et al (1991) Immunological markers of the subsets of systemic scleroderma and its overlap. Arch Immunol Ther Exp 39(4):381–390
25. Jarzabek-Chorzelska M et al (1990) Are ACA and Scl 70 antibodies mutually exclusive? Br J Dermatol 122(2):201–208
26. Bunn CC, Black CM (1999) Systemic sclerosis: an autoantibody mosaic. Clin Exp Immunol 117(2):207–208
27. Feghali-Bostwick C, Medsger TA Jr, Wright TM (2003) Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 48(7):1956–1963
28. Pauling JD, McHugh N (2012) The clinical aspects of autoantibodies. In: Varga J, et al. (ed) Scleroderma: from pathogenesis to comprehensive management. Springer Science+ Business Media. p. 209–225